More on Arena Pharmaceuticals (ARNA): Q3 beats on a per share basis but comes up short on...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

More on Arena Pharmaceuticals (NASDAQ:ARNA): Q3 beats on a per share basis but comes up short on revenue. Separately, the company announced that it had granted Ildong Pharmaceutical exclusive rights to market and distribute its weight-loss drug Belviq in South Korea, subject to regulatory approval of BELVIQ by the Korea Food and Drug Administration. Shares +1.6% AH.